ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1895

Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease

Shima Yasin1, Rachel Brown1, Ndate Fall2, Krista Solomon1, Scott Canna3, Charlotte Girard4, Cem Gabay5, Eduardo Schiffrin6, Andrew Sleight6, Alexei A. Grom7 and Grant Schulert8, 1Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, 3NIAMS, National Institutes of Health, Bethesda, MD, 4Division of Rheumatology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland, 5SCQM, Geneva, Switzerland, Geneva, Switzerland, 6AB2 Bio, Lausanne, Switzerland, 7Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States Minor Outlying Islands, 8Pediatric Rheumatology, Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cytokines and macrophage activation syndrome, IL-1/IL-18, Systemic JIA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Systemic juvenile idiopathic arthritis is an autoinflammatory childhood arthritis with prominent innate immune activity. Macrophage activation syndrome is a severe and potentially fatal complication of sJIA. IL-18 is felt to play a key role in pathogenesis of sJIA and in particular MAS; possibly through IFN-g activation. IL-18 binding protein (IL-18BP) is an endogenous inhibitor that binds IL-18 tightly. However, clinical effects of blocking IL-18 in sJIA are still unknown.

Objective: To examine serum IL-18 levels in sJIA patients with regards to disease activity, MAS features, and other novel MAS biomarkers. Additionally, we report the use of recombinant IL-18 BP (rIL-18BP) in a patient with severe, refractory sJIA and MAS.

Methods: Serum samples obtained from 20 established sJIA patients. Total IL-18, CXCL9 and S100 protein were measured. In addition, in one patient serial free IL-18 levels were determined. We compared IL-18 levels in patients with active vs inactive disease as well as with history of MAS vs no MAS.

Results:

Serum IL-18 levels were higher in patients with active sJIA (mean 52537 pg/ml ± 24442, N=10), but were still persistently elevated (2733 ± 889, N=10, upper limit of normal 540) in majority of patients with inactive disease (p=0.07). Patients with history of MAS had significantly higher IL-18 levels (63170 ± 29586, N=8) as compared to those without MAS history (3945 ± 1708, N=12, p=0.03). Only patients with fever had significantly higher IL-18 levels compared to their counter parts (P=0.03), while arthritis and elevated ESR or CRP showed no difference (p=0.1 and 0.08 respectively). We observed a weak but significant correlation between total IL-18 and CXCL9 (correlation coefficient of 0.4 (p=0.03) but not for S100A8/A9. Given these findings by us and others, we utilized Tadekinig alfa (rhIL-18BP) in a 5 year old male with sJIA and persistently elevated free IL-18 levels. His course was complicated by recurrent MAS, failure of all prior biologic treatments, chronic high dose steroids with flare of sJIA and MAS upon attempts to wean steroids. He was started on rhIL-18BP 2mg/kg/dose subcutaneous every 48h in addition to continuous IL-1 inhibition attempting to control disease and prevent MAS. His initial total and free serum IL-18 levels were high at 117356 pg/ml and 46.8 pg/ml respectively. Although his total IL-18 remained elevated after start of rhIL-18BP, free IL-18 was undetectable. In addition, since initiation of Tadekinig alfa, steroid dose was decreased by more than 50% with increase in linear growth. While on Tadekinig alfa, he developed two MAS episodes (triggered by parainfluenza and acute gastroenteritis), but both were mild and easily controlled.

Conclusion:

Total serum IL-18 levels were elevated in the majority of sJIA patients regardless of disease activity, with higher levels in patients with active disease and those with history of MAS. This indicates that IL-18 might be an important driver of sJIA and MAS. Use of rIL-18 BP improved patient disease course with less frequent and easily controlled MAS episodes. This response raises optimism about use of rIL-18 BP in patients with IL-18 driven disease preventing life-threatening MAS.


Disclosure: S. Yasin, None; R. Brown, None; N. Fall, None; K. Solomon, None; S. Canna, AB2Bio Ltd, 5; C. Girard, None; C. Gabay, Roche, Pfizer, AB2 Bio, 2,Sanofi, AB2 Bio, AbbVie, Pfizer, BMS, MSD, Roche, Novartis, 5; E. Schiffrin, AB2bio Ltd, 3; A. Sleight, Ab2 bio, 3; A. A. Grom, NovImmune, 2,Ab2 Bio, 2,Novartis Pharmaceutical Corporation, 5,Juno, 5; G. Schulert, Novartis Pharmaceutical Corporation, 5.

To cite this abstract in AMA style:

Yasin S, Brown R, Fall N, Solomon K, Canna S, Girard C, Gabay C, Schiffrin E, Sleight A, Grom AA, Schulert G. Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serum-interleukin-18-as-a-biomarker-for-systemic-juvenile-idiopathic-arthritis-and-macrophage-activation-syndrome-and-use-of-recombinant-human-il-18-bp-in-a-patient-with-refractory-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-interleukin-18-as-a-biomarker-for-systemic-juvenile-idiopathic-arthritis-and-macrophage-activation-syndrome-and-use-of-recombinant-human-il-18-bp-in-a-patient-with-refractory-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology